Basal Cell Carcinoma
Conditions
Brief summary
Retrospective and Prospective Observational Study in Patients With Advanced Basal Cell Carcinoma.
Detailed description
Basal cell carcinoma (BCC) is an epithelial tumor characterized by the malignant proliferation of keratinocytes in the basal layer of the epidermis. It is part, along with squamous cell carcinoma (SCC),non-melanoma skin cancer (NMSC) and accounts for 80% of all skin cancers and the most common skin cancer in the United States and Europe. Estimates of BCC incidence, however, are inaccurate since in most countries there is no cancer register collecting data on BCC incidence and many patients are treated on a territorial outpatient basis, making data collection and epidemiological analysis complex. In recent decades, there has been an increasing trend in patients with BCC, as well as a reduction in the average age of onset, with a consequent drastic increase in the social and economic cost of healthcare facilities. From these considerations, arises the need to investigate and characterize the profile of patients with advanced BCC, the clinical characteristics and the course of such neoplasm, and the choice of therapeutic options available.
Interventions
None listed
Sponsors
Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male and female patients aged ≥ 18 years 2. Patients diagnosed with advanced basal cell carcinoma of the skin, i.e. tumours included in at least one of the following categories: locally advanced carcinoma (not radically treatable by surgery and/or radiotherapy), carcinoma with lymph node and/or distant metastatic localisation 3. patients who have had at least one access (first visit or follow-up visit) at the dermatology or oncology outpatient clinic of the centres involved * Patients diagnosed with advanced BCC who have accessed the centre from 1 January 2016 until the date of activation of the centre will be included in the retrospective cohort; * Patients diagnosed with advanced BCC who have accessed the centre from the date of activation 4. Signature of informed consent
Exclusion criteria
Patients incapable of giving informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| clinical evolution, treatment and prognosis | from baseline through study completion, an average of 3 years | clinical profile of patient, the phenotypic and behavioural characteristic and the clinical course from baseline to follow-up. |
Countries
Italy
Contacts
Primary ContactKetty MD Peris
Outcome results
None listed